Talampanel

Talampanel (INN; development codes GYKI 537773 and LY300164) is a drug which has been investigated for the treatment of epilepsy,^[1][2] malignant gliomas,^[3] and amyotrophic lateral sclerosis (ALS).^[4]

Talampanel

Clinical data
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name (8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine
CAS Number	161832-65-1 N
PubChem CID	164509
ChemSpider	144217 N
UNII	CVS43XG1L5
ChEMBL	ChEMBL61872 N
CompTox Dashboard (EPA)	DTXSID10167259
ECHA InfoCard	100.230.001
Chemical and physical data
Formula	C19H19N3O3
Molar mass	337.379 g·mol−1
3D model (JSmol)	Interactive image
SMILES Nc4ccc(cc4)C(=NN2C(=O)C)c3cc1OCOc1cc3CC2C
InChI InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1 N Key:JACAAXNEHGBPOQ-LLVKDONJSA-N N
NY (what is this?)  (verify)

As of May 2010, results from the trial for ALS have been found negative.^[5] Talampanel is not currently under development.

Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system.^[6]

It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.^[7]